01 — At a Glance
The Agro-Chemical Roller Coaster That Forgot to Stop
PI Industries dropped a bombshell. Q3 FY26 revenue crashed 27.6% YoY to ₹1,376 crore. Quarterly PAT tumbled 39.6% to ₹311 crore (figures in ₹ million = ₹31.1 crore). Annualised EPS ₹82.08 (Q3 EPS ₹20.52 × 4). Full-year P/E now dancing at 34.2x — a premium to peers that makes even the most forgiving investor twitch. The culprit? A global agrochemical downcycle that refuses to end. Channel inventory remains elevated. Farmer income is crushed. And yet, management is oddly confident Q4 will be the inflection point. The stock is down 7.51% in three months, down 16.7% in six months. The market is clearly not buying the “bottom is here” narrative. We’re here to figure out if the market is wrong or management is smoking something.
Real Talk: This is a cyclical stock at a potentially cyclical bottom. Or it’s a value trap masquerading as cyclical. The difference is about 12 months and whether management’s “normalization starts Q4” actually happens. Show me proof or show me the exit door.
02 — Introduction
From Export Darling to Channel-Destocked Disaster
PI Industries is India’s leading agrochemical CDMO (contract research and development, contract development and manufacturing organisation) export player — think of them as the “Infosys of farming chemicals.” They mix molecules for global innovators like Syngenta, Corteva, and others who are too lazy (or regulated) to do it themselves. The company also sells branded agro-chemicals domestically in India. Sounds stable. Sounds safe. Sounds like exactly the kind of boring cash business that should quietly compound for 20 years.
Then 2025 happened. Chinese suppliers flooded the global market. Farmer income in India collapsed. Commodity prices tanked. Channel inventories swelled to obscene levels. And PI Industries, despite being a “niche CDMO exporter with stable margins,” got absolutely hammered because when the entire supply chain gets constipated with unsold inventory, even the best factories can’t operate at full capacity.
Management’s current pitch: “This is the tail end of the downcycle. Inventories are normalizing. We’ll see volume growth from Q4 FY26 onwards, with stronger momentum into FY27.” Translation: We hope the world stops choking on generic agrochemicals by March 2026. If not, we’ll sound equally confident in April.
The company has also pivoted into pharma (acquired TRM and Archimica in 2023 for ₹775 crore) and biologicals (acquired Plant Health Care Plc for £32.8 million in August 2024). These are long-term bets. They’re also unprofitable and burning cash today. But management sees them as the “next decade’s growth.” For income investors, this is a distraction. For growth hunters, this is a lifeline.
Concall Note (Feb 2026): Management explicitly said “Q3 moderation is primarily volume-led” but also claimed “we expect volume growth from the beginning of quarter 4 FY26.” They’re so confident about Q4 recovery, they might actually be right. Or they might be out of their minds. History will decide.
03 — Business Model: WTF Do They Even Make?
They Brew Molecules for the World. Then They Sell Them Back to Indian Farmers.
PI Industries has three operating platforms, and understanding them is critical to understanding why Q3 was a disaster.
1. Agro-Chemicals CSM Exports (80% of FY25 revenue — ₹4,940 crore): This is the crown jewel. PI receives a brief from global innovators: “We need 500 tonnes of this new molecule synthesized and manufactured to our specs.” PI says: “Done. Here are our multi-purpose plants, our chemists, and our IP-backed process expertise.” They hand over the finished good, customer pays, PI pockets 20-30% margins, repeat. It’s a B2B, high-margin, intellectually defensible business. Except when the entire global supply chain has excess inventory and everyone stops ordering.
2. Domestic Agro Brands (17% of revenue — ₹1,060 crore in 9M FY25): Branded generics. They license molecules, rebrand them, and sell to Indian farmers through their distribution network. Insecticides, fungicides, herbicides — the whole crop protection arsenal. Margins here are lower (mid-teens). But it’s supposed to be stable because farmers need these inputs every season. Except when farmers have no income because wheat prices are at 2015 levels, they don’t buy anything.
3. Pharma (3% of revenue — ₹130 crore in 9M FY25, down from ₹243 crore in 9M FY24): CRDMO services (contract R&D and manufacturing) for the pharma industry. Acquired from TRM and Archimica. Currently unprofitable and being positioned as a “multi-billion revenue opportunity by FY28.” Right now it’s just a cash drain wearing a growth story.
The unit economics: When the CSM export segment hums, 25-28% EBITDA margins are achievable. When it stalls (like now), margins compress to 22%. When you layer on the loss-making pharma arm and domestic agri weakness, you get Q3 FY26: a 22% OPM that sounds okay until you realize it’s down 400 basis points YoY.
💬 Quick question: Do you think PI Industries will actually return to normal volume growth in Q4, or are we looking at a multi-quarter slog? Drop your prediction in the comments.
04 — Financials Overview
Q3 FY26: The Numbers That Hurt
Result type: Quarterly Results | Q3 FY26 EPS: ₹20.52 | Annualised EPS (Q3×4): ₹82.08 | 9M FY26 PAT (9 months): ₹956 mn
| Metric (₹ Million) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 13,757 | 18,971 | 18,718 | -27.6% | -26.5% |
| Operating Profit | 3,027 | 5,514 | 5,409 | -45.1% | -44.0% |
| OPM % | 22.0% | 29.1% | 28.9% | -710 bps | -690 bps |
| PAT | 3,107 | 5,124 | 4,091 | -39.3% | -24.1% |
| EPS (₹) | 20.52 | 33.76 | 26.98 | -39.3% | -24.0% |
What Happened: Revenue down 27.6% YoY and 26.5% QoQ — meaning both year-on-year comparisons and quarter-on-quarter trends are screaming downturn, not stabilization. Operating margin compression of 710 basis points is apocalyptic for a CDMO company that’s supposed to have “stable margins.” PAT down 39.3% YoY because tax rate was lower last year (boosting comparison), but the underlying operational destruction is real. Management wants credit for annualized 9M EBITDA margin of 27% (vs full-year guided 25-26%), but Q3’s 22% OPM is the forward indicator.
05 — Valuation: Fair Value Range
What Is This Company Actually Worth When The Cycle Turns?
Join 10,000+ investors who read this every week.
